Ability of Urografin Density Gradients to Separate Nonculturable Subpopulations of Escherichia coli

Poster presentado a 11th International Symposium on Microbial Ecology(ISME -11)celebrado en Viena del 20 al 25 de agosto de 2006

Procedimiento de refutación para un conjunto de restricciones sobre documentos XML

We present a prototype that implements a set of logical rules to prove the satis ability for a class of speci cations on XML documents. Speci cations are given by means of constraints built on Boolean XPath patterns. The main goal of this tool is to test if a given speci cation is satis able or not, showing the history of the execution. It can also be used to test if a given document is a model of a given speci cation and, as a subproduct, it allows to look for all the relations (monomorphisms) between two patterns or the result of doing some operations by combining patterns in di erent ways. The results of these operations are visually shown and therefore the tool makes these operations more understandable. The implementation of the algorithm has been written in Prolog but the prototype has a Java interface for an easy and friendly use.

Price Premium for High-Efficiency Refrigerators and Calculation of Price-Elasticities for Close-Substitutes: Combining Hedonic Pricing and Demand Systems

21 p.

Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results

Based on numerous pharmacological studies that have revealed an interaction between cannabinoid and opioid systems at the molecular, neurochemical, and behavioral levels, a new series of hybrid molecules has been prepared by coupling the molecular features of two well-known drugs, ie, rimonabant and fentanyl. The new compounds have been tested for their affinity and functionality regarding CB1 and CB2 cannabinoid and mu opioid receptors. In [S-35]-GTP.S (guanosine 5'-O-[gamma-thio] triphosphate) binding assays from the post-mortem human frontal cortex, they proved to be CB1 cannabinoid antagonists and mu opioid antagonists. Interestingly, in vivo, the new compounds exhibited a significant dual antagonist action on the endocannabinoid and opioid systems.